Evaluating several methods of JAK2 V617F mutation-genotyping to predict the risk of getting polycythemia vera and other myeloproliferative neoplasm diseases

Nguyen Thy Ngoc, Bui Bich Hau, Pham Hoang Nam, Tran Tuan Anh, Do Thi Trang, Nguyen Thi Xuan
Author affiliations

Authors

  • Nguyen Thy Ngoc University of Science and Technology of Hanoi https://orcid.org/0000-0002-3181-9209
  • Bui Bich Hau
  • Pham Hoang Nam
  • Tran Tuan Anh
  • Do Thi Trang
  • Nguyen Thi Xuan

DOI:

https://doi.org/10.15625/1811-4989/15666

Abstract

Polycythemia vera, essential thrombocythemia and primary myelofibrosis are members of the Philadelphia negative chronic subgroup of Myeloproliferative neoplasm. Published studies showed that the mutation JAK2 V617F is mostly responsible for the diseases; therefore, an accurate, low-cost and rapid molecular method to identify this mutation is important in screening and early diagnostic of these diseases. Different methods for genotyping of JAK2 V617F have been proposed. In this study, we evaluated the quality and cost-effectiveness of three genotyping methods, i.e., PCR-ARMS, PCR-RFLP, Sanger sequencing, to determine the appropriate genotyping for JAK2 V617F and predicted in silico the effect of this mutation on the structure and function of Janus kinase 2 protein. Results showed that the Sanger sequencing and PCR-RFLP genotyping methods were more accurate than PCR-ARMS. PCR-RFLP was also more rapid and economical than the other methods. In silico studies also demonstrated that the JAK2 V617F mutation had a large effect on the activity of corresponding protein. These results provided the initial data for further studies on genetic screening and prediction of myeloproliferative neoplasm and other related diseases in the Vietnamese population.

Downloads

Download data is not yet available.

Downloads

Published

13-10-2021

How to Cite

Thy Ngoc, N., Bich Hau, B., Hoang Nam, P., Tuan Anh, T., Thi Trang, D., & Thi Xuan, N. (2021). Evaluating several methods of JAK2 V617F mutation-genotyping to predict the risk of getting polycythemia vera and other myeloproliferative neoplasm diseases. Vietnam Journal of Biotechnology, 19(3), 433–440. https://doi.org/10.15625/1811-4989/15666

Issue

Section

Articles

Most read articles by the same author(s)